Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 4/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12469375 | 0.87 | KEAP1 (0.47) | MEN1KMT2AKDM4EKEAP1ALOX5AP | |
| SCHEMBL1290949 | 0.86 | KDM4E (0.46) | MEN1KMT2AKDM4EKEAP1ALDH1A1 | |
| SCHEMBL1259549 | 0.85 | MEN1 (0.48) | MEN1KMT2AKDM4EKEAP1ALOX5AP | |
| SCHEMBL1290681 | 0.82 | HSPB1 (0.64) | MEN1KMT2AKDM4EHSPB1ALDH1A1 | |
| SCHEMBL12469294 | 0.80 | KDM4E (0.54) | MEN1KMT2AKDM4EKEAP1ALDH1A1 | |
| SCHEMBL3509911 | 0.76 | MEN1 (0.48) | MEN1KMT2AKDM4EKEAP1ALOX5AP | |
| SCHEMBL3134874 | 0.76 | MEN1 (0.53) | MEN1KMT2AKDM4EKEAP1ALOX5AP | |
| SCHEMBL4314966 | 0.76 | MEN1 (0.53) | MEN1KMT2AKDM4EKEAP1ALOX5AP | |
| SCHEMBL15301083 | 0.76 | RAB9A (0.52) | KDM4ERAB9ALIPE | |
| SCHEMBL1290926 | 0.75 | KCNQ3 (0.56) | MEN1KMT2AKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139808-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20210017134-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-21 | — | — | US | disclosed |
| US-20200031773-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-01-30 | — | — | US | disclosed |
| US-20180265471-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-20 | — | — | US | disclosed |
| US-20170298023-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20150105432-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. | 2015-04-16 | — | — | US | disclosed |
| US-8946437-B2 | 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| EP-2624833-B1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-20130267565-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| EP-2624833-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN- 3 - YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | Otsuka Pharmaceutical Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012046825-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN- 3 - YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105432-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, IDH2, GLS2 | MEN1 617/4885KMT2A 126/4885KDM4E 480/4885 |
| US-20230139808-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, IDH2, MDH2 | MEN1 639/4885KMT2A 141/4885KDM4E 446/4885 |
| US-20130267565-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, MDH2, IDH2 | MEN1 616/4885KMT2A 108/4885KDM4E 413/4885 |
| US-20180265471-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, GLS2, IDH2 | MEN1 619/4885KMT2A 132/4885KDM4E 488/4885 |
| US-20170298023-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | IDH2, MDH2, HCCS | MEN1 599/4885KMT2A 110/4885KDM4E 404/4885 |
| US-20200031773-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, GLS2, IDH2 | MEN1 619/4885KMT2A 132/4885KDM4E 488/4885 |
| US-20210017134-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, GLS2, IDH2 | MEN1 619/4885KMT2A 132/4885KDM4E 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.